CLARITY 2.0 RECEIVES ETHICS APPROVAL
IN AUSTRALIA PHASE 3 COVID-19 STUDY
• First ethics approval received for CLARITY 2.0 feasibility/Phase 3 study in patients with
COVID-19 in Australia
• Six sites planned to recruit across New South Wales, Victoria and Queensland
• Recruitment and dosing expected to commence in Australia in January
• Study previously approved in India1 and open for recruitment
• If effective in the treatment of COVID-19, DMX-200 may be equally effective across all strains
and other infection-related pneumonias6
Ann: Ethics Approval in Australia for Phase 3 COVID-19 Study, page-2
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.5¢ |
Change
-0.010(2.20%) |
Mkt cap ! $247.9M | |||
| Open | High | Low | Value | Volume |
| 45.0¢ | 45.8¢ | 43.8¢ | $701.3K | 1.564M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 111371 | 44.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.0¢ | 8072 | 1 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |